MACROPHAGE CYTOKINES RENDER WEHI-3B TUMOR-CELLS SUSCEPTIBLE TO CYTOSTASIS BY PROSTAGLANDINS

被引:5
作者
BENEFRAIM, S
TAK, C
BONTA, IL
机构
[1] ERASMUS UNIV,FAC MED,INST PHARMACOL,3000 RD ROTTERDAM,NETHERLANDS
[2] TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL
来源
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 1990年 / 40卷 / 02期
关键词
D O I
10.1016/0952-3278(90)90161-D
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The growth of the murine myelomonocytic leukemia tumor, WEHI-3B, has been shown to be inhibited by a two-step treatment: first, incubation for one hour with either interleukin-1 (human recombinant IL-1α or tumor necrosis factor (human recombinant TNF-α); second, subsequent exposure to prostaglandins. Preincubation with IL-1 rendered the tumor cells more susceptible to subsequent treatment with either prostaglandin E2 or to the stable synthetic analogue of prostacyclin DC-PGI2. Preincubation with TNF-α rendered the tumor cells more susceptible to further treatment with PGE2 but not with DC-PGI2. Preconditioning of the tumour cells with either IL-1α or TNFα did not affect cytostasis by subsequent culture of tumor cells in presence of either one of the cytokines. It is concluded that the interactions between macrophage cytokines and prostaglandins in enhancement of antitumor activity might imply first binding or induction of certain modifications in the tumor cells by the cytokines which render the cells more susceptible to exposure to prostaglandins. © 1990.
引用
收藏
页码:163 / 167
页数:5
相关论文
共 28 条
[1]  
AGGARWAL B B, 1987, Drugs of the Future, V12, P891
[2]   CHARACTERIZATION OF RECEPTORS FOR HUMAN-TUMOR NECROSIS FACTOR AND THEIR REGULATION BY GAMMA-INTERFERON [J].
AGGARWAL, BB ;
EESSALU, TE ;
HASS, PE .
NATURE, 1985, 318 (6047) :665-667
[3]  
DINARELLO CA, 1983, J IMMUNOL, V130, P890
[4]   THE INFLUENCE OF LIPOXYGENASE INHIBITORS ON THE INVITRO PRODUCTION OF HUMAN LEUKOCYTIC PYROGEN AND LYMPHOCYTE ACTIVATING FACTOR (INTERLEUKIN-1) [J].
DINARELLO, CA ;
BISHAI, I ;
ROSENWASSER, LJ ;
COCEANI, F .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1984, 6 (01) :43-50
[5]   INTERLEUKIN-1 [J].
DINARELLO, CA .
REVIEWS OF INFECTIOUS DISEASES, 1984, 6 (01) :51-95
[6]  
ELLIOTT GR, 1989, CANCER IMMUNOL IMMUN, V28, P74
[7]   A HIGHLY SENSITIVE CELL-LINE, WEHI-164 CLONE 13, FOR MEASURING CYTOTOXIC FACTOR TUMOR-NECROSIS-FACTOR FROM HUMAN-MONOCYTES [J].
ESPEVIK, T ;
NISSENMEYER, J .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (01) :99-105
[8]  
FARRAR WL, 1985, J IMMUNOL, V135, P1153
[9]  
GREEN S, 1982, J NATL CANCER I, V68, P997
[10]  
HASS PE, 1985, J BIOL CHEM, V260, P2214